Pfizer to Use ActivX Technology in Drug Discovery, Proteomic Profiling

NEW YORK, Feb. 9 (GenomeWeb News) - Pfizer researchers will use ActivX's high-throughput protein analysis in drug discovery, proteomic profiling, compound selectivity, and other projects, ActivX said today.

ActivX Biosciences, a subsidiary of Tokyo-based Kyorin Pharmaceuticals, also said that it and the drug giant will collaborate on multiple future projects.

Financial details of the agreement, which is part of an expanding partnership between the two companies, included an upfront technology access fee, along with research support payments by Pfizer.

As GenomeWeb News reported earlier this month, ActivX was acquired by Kyorin Pharameceuticals. The company paid $21 million for the proteomics shop which it wholly owns and plans to use as its USdrug-discovery and development center.